STOCK TITAN

COO of 20/20 Biolabs (AIDX) granted 150,000 options at $1.88

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

20/20 Biolabs, Inc. Chief Operating Officer Zhou Jiming received a grant of stock options covering 150,000 shares of Common Stock. The options have an exercise price of $1.88 per share, were granted on April 2, 2026, and expire on April 2, 2036. Following this grant, Zhou holds 150,000 stock options directly.

Positive

  • None.

Negative

  • None.
Insider Zhou Jiming
Role Chief Operating Officer
Type Security Shares Price Value
Grant/Award Stock Option 150,000 $0.00 --
Holdings After Transaction: Stock Option — 150,000 shares (Direct)
Footnotes (1)
Options granted 150,000 options Stock option grant to COO on April 2, 2026
Exercise price $1.88 per share Exercise price of granted stock options
Expiration date April 2, 2036 Option term for 150,000 granted options
Options owned after grant 150,000 options Total stock options directly held following transaction
Transaction price per option $0.00 Reported transaction price per option in grant
Stock Option financial
"security_title: "Stock Option""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: "1.8800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-04-02T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
grant/award acquisition financial
"transaction_action: "grant/award acquisition""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zhou Jiming

(Last)(First)(Middle)
C/O 20/20 BIOLABS, INC.,
5810 GAITHER ROAD, SUITE 235

(Street)
GAITHERSBURG MARYLAND 20877

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
20/20 Biolabs, Inc. [ AIDX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$1.8804/02/2026A150,00004/02/202604/02/2036Common Stock150,000$0150,000D
Explanation of Responses:
/s/ Jiming Zhou04/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did 20/20 Biolabs (AIDX) COO Zhou Jiming report in this Form 4?

Zhou Jiming reported receiving a grant of stock options for 150,000 shares of 20/20 Biolabs Common Stock. The options were awarded on April 2, 2026, giving him the right to buy shares at a fixed exercise price in the future before expiration.

How many 20/20 Biolabs (AIDX) stock options were granted to Zhou Jiming?

The filing shows a grant of stock options covering 150,000 shares of 20/20 Biolabs Common Stock. This entire amount is reported as directly owned following the transaction, indicating Zhou’s option position from this grant totals 150,000 shares.

What is the exercise price of the stock options granted to 20/20 Biolabs (AIDX) COO?

The stock options have an exercise price of $1.88 per share. This means Zhou can choose to purchase 20/20 Biolabs Common Stock at $1.88 for each optioned share during the option term, regardless of the market price at that time.

When do Zhou Jiming’s 20/20 Biolabs (AIDX) stock options expire?

The options expire on April 2, 2036, according to the Form 4. Until that expiration date, Zhou holds the right, but not the obligation, to exercise these options at the fixed $1.88 per share exercise price for the 150,000 underlying shares.

Is the 20/20 Biolabs (AIDX) Form 4 transaction a purchase or a grant?

The transaction is classified as a grant or award acquisition of stock options, not an open-market share purchase. The Form 4 uses transaction code “A” and describes it as a grant, reflecting compensation-related option issuance rather than a market trade.